Urolithin A for Mitochondrial Biogenesis
Urolithin A primarily drives mitophagy, which is related to but distinct from biogenesis.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 500-1,000 mg/day of urolithin A with food; the mechanism is mitophagy rather than biogenesis
- Expected timeframe
- 4 months
Protocol
- form
- Synthesised urolithin A such as Mitopure
- duration
- 4 months
- co factor
- Take with food. Evidence is mixed and the mechanistic framing needs correcting. Urolithin A primary documented action is mitophagy - clearing damaged mitochondria - rather than mitochondrial biogenesis, which is the creation of new mitochondria driven principally by PGC-1alpha and stimulated most reliably by endurance exercise. The two processes are complementary parts of mitochondrial quality control, and improved mitophagy can secondarily support biogenesis, but they are distinct. Human trials show changes in muscle mitochondrial gene expression and acylcarnitine profiles consistent with improved mitochondrial function; none has directly measured mitochondrial density or biogenesis by biopsy morphometry.
- titration
- Up to 1,000 mg/day as used in trials
- starting dose
- 500 mg/day with food
Evidence
What the studies say
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
Andreux PA, Blanco-Bose W, Ryu D
Urolithin A was bioavailable and safe up to 1000 mg and modulated mitochondrial gene expression in skeletal muscle
Impact of the Natural Compound Urolithin A on Health, Disease, and Aging
DAmico D, Andreux PA, Valdes P +3 more
Urolithin A stimulates mitophagy and improves muscle and metabolic markers across models
Safety
Caveats
Endurance exercise is by far the most reliable stimulus for mitochondrial biogenesis in humans, with decades of muscle biopsy evidence behind it, and no supplement approaches it - anything claiming to build mitochondria should be judged against that comparison. Urolithin A has the best human mitochondrial biomarker data of any supplement in this category, but its documented mechanism is clearing damaged mitochondria rather than creating new ones, and mitochondrial density has not been measured after supplementation. Safety of urolithin A: well tolerated at 500-1,000 mg/day over 4 months, with no significant adverse effects reported and FDA GRAS status granted, though no upper limit is established and long-term data beyond about a year are absent. Mild gastrointestinal upset is occasionally reported. Interactions have not been systematically studied. Safety in pregnancy and breastfeeding is not established. Nearly all trials are funded by the ingredient developer, which warrants caution about effect sizes. Pomegranate products are an unreliable route, since only 30-40% of people carry the gut bacteria that produce urolithin A from ellagitannins.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.